| First Author | Song T | Year | 2016 |
| Journal | FASEB J | Volume | 30 |
| Issue | 1 | Pages | 214-29 |
| PubMed ID | 26373801 | Mgi Jnum | J:237605 |
| Mgi Id | MGI:5816221 | Doi | 10.1096/fj.15-274860 |
| Citation | Song T, et al. (2016) Canonical transient receptor potential 3 channels activate NF-kappaB to mediate allergic airway disease via PKC-alpha/IkappaB-alpha and calcineurin/IkappaB-beta pathways. FASEB J 30(1):214-29 |
| abstractText | The purpose of this study was to determine the role of canonical transient receptor potential 3 (TRPC3) channel in allergen-induced airway disease (AIAD) and its underlying signaling mechanisms. The procedures included (1) intravenous injection of lentiviral TRPC3 channel or nonsilencing short hairpin ribonucleic acid (shRNA) to make the channel knockdown (KD) or control mice, (2) allergen sensitization/challenge to induce AIAD, (3) patch-clamp recording and Ca(2+) imaging to examine the channel activity, and (4) gene manipulations and other methods to determine the underlying signaling mechanisms. The findings are that (1) intravenous or intranasal delivery of TRPC3 channel lentiviral shRNAs or blocker 1-[4-[(2,3,3-trichloro-1-oxo-2-propen-1-yl)amino]phenyl]-5-(trifluoromethyl)-1H-p yrazole-4-carboxylic acid prevents AIAD in mice, (2) TRPC3 channel KD and overexpression, respectively, blocks and augments protein kinase C-alpha/nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor-alpha (PKC-alpha/IkappaB-alpha)-mediated or calcineurin/IkappaB-beta-dependent, NF-kappaB-dependent allergen-induced airway smooth muscle cell (ASMC) hyperproliferation and cyclin D1 (an important cell proliferation molecule) induction, and (3) the changes of the major molecules of the PKC-alpha/IkappaBalpha- and calcineurin/IkappaB-beta-dependent NF-kappaB signaling pathways are also observed in asthmatic human ASMCs. The conclusions are that TRPC3 channels plays an essential role in AIAD via the PKC-alpha/IkappaB-alpha- and calcineurin/IkappaB-beta-dependent NF-kappaB signaling pathways, and lentiviral shRNA or inhibitor of TRPC3 channels may become novel and effective treatments for AIAD. |
